ES2082217T3 - Procedimiento de amplificacion de la señal de emision de un compuesto luminiscente. - Google Patents

Procedimiento de amplificacion de la señal de emision de un compuesto luminiscente.

Info

Publication number
ES2082217T3
ES2082217T3 ES91913539T ES91913539T ES2082217T3 ES 2082217 T3 ES2082217 T3 ES 2082217T3 ES 91913539 T ES91913539 T ES 91913539T ES 91913539 T ES91913539 T ES 91913539T ES 2082217 T3 ES2082217 T3 ES 2082217T3
Authority
ES
Spain
Prior art keywords
compound
emission signal
luminiscent
amplification
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913539T
Other languages
English (en)
Inventor
Gerard Mathis
Christophe Dumont
Daniel Aspe
Muriel Foyentin
Etienne Jean-Pierre Jolu
Dominique Nuti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CIS Bio International SA
Original Assignee
CIS Bio International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CIS Bio International SA filed Critical CIS Bio International SA
Application granted granted Critical
Publication of ES2082217T3 publication Critical patent/ES2082217T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Luminescent Compositions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCESO DE AMPLIFICACION DE LA SEÑAL DE EMISION DE UN COMPUESTO LUMINISCENTE EN UNA DOSIFICACION POR LUMINISCENCIA, ASI COMO SU UTILIZACION EN UN PROCESO DE DETECCION Y/O DE DETERMINACION POR LUMINISCENCIA DE UN PRODUCTO DE ANALISIS EN UN MEDIO SUSCEPTIBLE DE CONTENERLO.
ES91913539T 1990-07-13 1991-07-12 Procedimiento de amplificacion de la señal de emision de un compuesto luminiscente. Expired - Lifetime ES2082217T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9008981A FR2664699B1 (fr) 1990-07-13 1990-07-13 Procede d'amplification du signal d'emission d'un compose luminescent.

Publications (1)

Publication Number Publication Date
ES2082217T3 true ES2082217T3 (es) 1996-03-16

Family

ID=9398708

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913539T Expired - Lifetime ES2082217T3 (es) 1990-07-13 1991-07-12 Procedimiento de amplificacion de la señal de emision de un compuesto luminiscente.

Country Status (11)

Country Link
US (1) US5512493A (es)
EP (1) EP0539477B1 (es)
JP (1) JP3117459B2 (es)
AT (1) ATE130096T1 (es)
AU (1) AU8198091A (es)
DE (1) DE69114499T2 (es)
DK (1) DK0539477T3 (es)
ES (1) ES2082217T3 (es)
FR (1) FR2664699B1 (es)
GR (1) GR3018429T3 (es)
WO (1) WO1992001225A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399397B1 (en) 1992-09-14 2002-06-04 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5736410A (en) 1992-09-14 1998-04-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US6159686A (en) * 1992-09-14 2000-12-12 Sri International Up-converting reporters for biological and other assays
US6238931B1 (en) * 1993-09-24 2001-05-29 Biosite Diagnostics, Inc. Fluorescence energy transfer in particles
FR2735238B1 (fr) * 1995-06-09 1997-09-05 Cis Bio Int Utilisation d'un complexe phycobiliproteine-peptide de liaison en tant que traceur fluorescent
FI963989A (fi) * 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US20050227294A1 (en) * 1997-09-15 2005-10-13 Molecular Devices Corporation Molecular modification assays involving lipids
US7632651B2 (en) * 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
FR2769315B1 (fr) * 1997-10-03 2001-06-08 Cis Bio Int Conjugues fluorescents de nucleosides ou de nucleotides, leur procede de preparation et leur utilisation
JP2002504689A (ja) 1998-02-18 2002-02-12 デイド・ベーリング・インコーポレイテッド 複数の検体の検出において使用するための化学ルミネセンス組成物
EP1925320A3 (en) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
FR2778744B1 (fr) 1998-05-14 2000-06-23 Cis Bio Int Dosage immunologique de la chromogranine a humaine (cga) anticorps, reactifs et trousses utilisables pour ce dosage
US5998146A (en) * 1998-07-17 1999-12-07 Wallac Oy Homogeneous luminescence assay method based on energy transfer
US6235479B1 (en) 1999-04-13 2001-05-22 Bio Merieux, Inc. Methods and devices for performing analysis of a nucleic acid sample
FR2809817B1 (fr) * 2000-06-02 2003-08-15 Cis Bio Int Procede de detection de presence d'un liquide dans un melange
DE10153829A1 (de) 2001-11-05 2003-05-28 Bayer Ag Assay basierend auf dotierten Nanoteilchen
EP1355159A1 (de) * 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verwendungen von Fragmenten der Carbamoylphosphat Synthetase 1 (CPS 1) für die Diagnose von Entzündungserkrankungen und Sepsis
EP1355158A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker
AU2003287384A1 (en) * 2002-10-30 2004-06-07 Pointilliste, Inc. Systems for capture and analysis of biological particles and methods using the systems
AU2003290561A1 (en) * 2003-02-10 2004-09-06 Dana Ault-Riche Self-assembling arrays and uses thereof
US20050095648A1 (en) * 2003-10-30 2005-05-05 Mario Geysen Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
WO2005067980A2 (en) * 2004-01-12 2005-07-28 Pointilliste, Inc. Design of therapeutics and therapeutics
US7943294B2 (en) * 2004-07-30 2011-05-17 Hologic, Inc. Methods for detecting oncofetal fibronectin
DE102004045705A1 (de) * 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen
EP1805188A4 (en) * 2004-09-30 2010-03-03 Mds Analytical Technologies Us COMPLEXES OF LUMINESCENT LANTHANIDES
DE102006021406B4 (de) 2006-05-08 2008-08-07 B.R.A.H.M.S Aktiengesellschaft In vitro Verfahren zur Früherkennung von arznei- und suchtmittelinduzierten Leberschäden und zur Erkennung der bereits erreichten Stufe der Leberschädigung
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
DE102007022367A1 (de) 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
US20130183696A1 (en) 2010-09-15 2013-07-18 Constance Neely Wilson Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
US9653691B2 (en) * 2012-12-12 2017-05-16 Universal Display Corporation Phosphorescence-sensitizing fluorescence material system
WO2016063304A1 (en) 2014-10-21 2016-04-28 Council Of Scientific & Industrial Research Luminescent lanthanide complexes and method of preparation thereof
US10138267B2 (en) 2015-04-06 2018-11-27 Hunan Skyworld Biotechnologies Co. Ltd. Bioconjugates of heterocyclic compounds
BR112018010269A2 (pt) 2015-11-27 2019-02-05 Brahms Gmbh mr-proadm como marcador para o status do volume extracelular de um indivíduo
US9834808B2 (en) 2016-01-21 2017-12-05 SeLux Diagnostics, Inc. Methods for rapid antibiotic susceptibility testing
MX2018008906A (es) 2016-01-21 2019-01-10 Selux Diagnostics Inc Metodos para pruebas rapidas de susceptibilidad antimicrobiana.
FR3051556A1 (fr) * 2016-05-18 2017-11-24 Biocytex Utilisation de marqueurs fluorescents pour la detection de cible biologique dans un echantillon
US20190178894A1 (en) 2016-08-09 2019-06-13 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event
US20190178897A1 (en) 2016-08-09 2019-06-13 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating organ dysfunction
CA3048213A1 (en) 2016-12-23 2018-06-28 Eric Stern Methods for improved rapid antimicrobial susceptibility testing
EP3577465B1 (en) 2017-02-02 2023-03-29 B.R.A.H.M.S GmbH Proadm as marker indicating an adverse event
WO2018220129A1 (en) 2017-05-31 2018-12-06 B.R.A.H.M.S Gmbh Mmp-8 as a marker for identifying infectious disease
EP4027145A1 (en) 2017-09-13 2022-07-13 B.R.A.H.M.S GmbH Pro-adm for therapy monitoring of intensive care unit patients
CN111094986B (zh) 2017-09-13 2023-11-10 B.R.A.H.M.S有限公司 基于肾上腺髓质素前体的指导流体治疗的方法
WO2019053124A1 (en) 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh PROADRENOMEDULINE AS AN INDICATOR FOR RENAL REPLACEMENT THERAPY IN SERIOUSLY PATIENT PATIENTS
EP3502691A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
EP3971573A1 (en) 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
US20200319212A1 (en) 2017-12-20 2020-10-08 B.R.A.H.M.S Gmbh Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
WO2019122089A1 (en) 2017-12-20 2019-06-27 B.R.A.H.M.S Gmbh Antibiotic therapy guidance based on pro-adm
EP3578989A1 (en) 2018-06-06 2019-12-11 B.R.A.H.M.S GmbH Pro-adm for prognosis of trauma-related complications in polytrauma patients
EP3608673A1 (en) 2018-08-08 2020-02-12 B.R.A.H.M.S GmbH Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
WO2020156988A1 (en) 2019-01-28 2020-08-06 B.R.A.H.M.S Gmbh Method to predict treatment response in patients with nocturnal enuresis
BR112021016597A2 (pt) 2019-02-21 2021-11-03 Brahms Gmbh Diagnóstico ou prognóstico de eventos adversos pós-cirúrgicos
CA3124744A1 (en) 2019-03-29 2020-10-08 B.R.A.H.M.S Gmbh Prescription of remote patient management based on biomarkers
EP3715851A1 (en) 2019-03-29 2020-09-30 B.R.A.H.M.S GmbH Prescription of remote patient management based on biomarkers
AU2020340381A1 (en) 2019-08-27 2022-04-07 SeLux Diagnostics, Inc. Systems and methods for performing antimicrobial susceptibility testing
WO2021204770A1 (en) 2020-04-06 2021-10-14 B.R.A.H.M.S Gmbh Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (sars)
WO2021204984A1 (en) 2020-04-09 2021-10-14 B.R.A.H.M.S Gmbh Biomarkers for the diagnosis of respiratory tract infections
AU2022405688A1 (en) 2021-12-08 2024-06-06 B.R.A.H.M.S Gmbh Biomarkers for prognosis of early onset preeclampsia
WO2023110832A1 (en) 2021-12-13 2023-06-22 UNIVERSITé LAVAL Biomarkers for the prediction of preterm birth
WO2024121392A1 (en) 2022-12-08 2024-06-13 B.R.A.H.M.S Gmbh Multiple sflt-1 measurements for prognosis of early onset preeclampsia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542104A (en) * 1983-04-06 1985-09-17 The Board Of Trustees Of The Leland Stanford Jr. Univ. Phycobiliprotein fluorescent conjugates
FR2570703B1 (fr) * 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
JPS61128169A (ja) * 1984-11-27 1986-06-16 Mitsubishi Chem Ind Ltd 免疫分析法
US4822733A (en) * 1985-05-28 1989-04-18 Amoco Corporation Lifetime-resolved assay procedures
WO1987007955A1 (en) * 1986-06-17 1987-12-30 Baxter Travenol Laboratories, Inc. Homogeneous fluoroassay methods employing fluorescent background rejection and water-soluble rare earth metal chelate fluorophores
FR2624862B1 (fr) * 1987-12-18 1990-06-08 Oris Ind Cryptates de terres rares, procedes d'obtention, intermediaires de synthese et application a titre de marqueurs fluorescents
GB8820887D0 (en) * 1988-09-06 1988-10-05 Atomic Energy Authority Uk Detecting selected species

Also Published As

Publication number Publication date
FR2664699B1 (fr) 1995-08-18
EP0539477A1 (fr) 1993-05-05
GR3018429T3 (en) 1996-03-31
JPH06500852A (ja) 1994-01-27
EP0539477B1 (fr) 1995-11-08
US5512493A (en) 1996-04-30
ATE130096T1 (de) 1995-11-15
JP3117459B2 (ja) 2000-12-11
DE69114499D1 (de) 1995-12-14
FR2664699A1 (fr) 1992-01-17
DK0539477T3 (da) 1995-12-11
WO1992001225A1 (fr) 1992-01-23
AU8198091A (en) 1992-02-04
DE69114499T2 (de) 1996-03-28

Similar Documents

Publication Publication Date Title
ES2082217T3 (es) Procedimiento de amplificacion de la señal de emision de un compuesto luminiscente.
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
EA200400329A1 (ru) Способы амплификации нуклеиновых кислот
EA200000457A1 (ru) Способ и система для обнаружения аналита
DE69940067D1 (de) Ger einheiten die zielmaterialbindende farbstoffe gebrauchen
EP1383914A4 (en) IMPROVED METHOD FOR DETECTING ATP
DE69735127D1 (de) Enzymsensor
ATE306561T1 (de) Verfahren zur quantifizierung eines analyten
ATE426041T1 (de) Zirkulare sonden amplifizierung (cpa) von zirkularisierten nucleinsaure-molekulen
DE69130564D1 (de) Protein-nukleinsäuresonden und selbige verwendende immunoassays
ATE269977T1 (de) Bindungsbeschleunigungsverfahren zum nachweis von analyten
AU7532501A (en) Method for increasing luminescence assay sensitivity
FR2664702B1 (fr) Procede de reduction d'interferences dans un dosage par fluorescence.
DK13785A (da) Polyhydroxybenzoesyrederivater
ATE513058T1 (de) Verdrängungsassay zur detektion von nukleinsäureoligomer-hybridisierungsereignissen
WO2003005028A8 (fr) Procede de selection d'agents bio-actifs par couplage de luminescence et systeme cellulaire vivant pour la mise en oeuvre de ce procede
FR2791141B1 (fr) Procede de reduction de l'extinction de fluorescence due au milieu de mesure
ATE386140T1 (de) Methoden und reagenzien zur in situ amplifizierung
DE60040874D1 (de) Amplifizierung von hiv-1 sequenzen zur detektion ven einhergehen
ATE323995T1 (de) Schätzung der kanalparameter mittels maximalwahrscheinlichkeitsschätzung
ES2256224T3 (es) Deteccion de proteasas o de peptidasas por fluorescencia.
ATE269417T1 (de) Verfahren zur erkennung und messung von gespleisten nukleinsäuren
IT1267410B1 (it) Procedimento per la determinazione di biomolecole mediante un sistema di amplificazione enzimatica.
FI990991A (fi) Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi
ATE272125T1 (de) Enzymatisch katalysierte signalamplifizierung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539477

Country of ref document: ES